Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;12(2):227-241.
doi: 10.1007/s40119-023-00305-w. Epub 2023 Feb 9.

Risk and Management of Patients with Cancer and Heart Disease

Loreena Hill  1   2 , Bruno Delgado  3   4 , Ekaterini Lambrinou  5 , Tara Mannion  6   7 , Mark Harbinson  8 , Claire McCune  9   10
Affiliations
Review

Risk and Management of Patients with Cancer and Heart Disease

Loreena Hill et al. Cardiol Ther. 2023 Jun.

Abstract

Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient's myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients' functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure.

Keywords: Anthracycline; Cardiotoxicity; Heart failure; Risk stratification.

PubMed Disclaimer

Conflict of interest statement

Loreena Hill: honorarium from Vifor Pharma. Claire McCune: received funding from The Heart Trust Fund Registered Charity Number: NIC100399 (“Late Anthracycline Induced Cardiotoxicity—Childhood Cancer Survivors”; see https://clinicaltrials.gov/ct2/show/NCT04852965). Bruno Delgado, Ekaterini Lambrinou, Tara Mannion and Mark Harbinson have nothing to disclose.

Figures

Fig. 1
Fig. 1
Surveillance strategy for anthracycline-treated patients. Adapted from the ESC 2022 cardio-oncology guidelines. If Mean Heart Dose (MHD) is not available from patient records, the prescribed dose may be utilised. A MHD ≥15 Gy equates to ≥35Gy prescribed dose; A MHD 5-15 Gy equates to 15-34Gy prescribed dose; A MHD <5 Gy equates to <15 Gy prescribed dose [4]. AC anthracycline, BP blood pressure, BMI body mass index, CV cardiovascular, D.E. doxorubicin equivalent, ECG electrocardiogram, Gy grays, Hx history, M months, MHD mean heart dose, NP natriuretic peptide, RTx radiotherapy, Tx treatment, U&E urea and electrolytes, Y years. * If abnormal, refer to cardio-oncology;(*) consider cardio-oncology referral
Fig. 2
Fig. 2
Specialized multidisciplinary teams embedded within the cardio-oncology service
See this image and copyright information in PMC

References

    1. de Boer RA, Meijers WC, van der Meer P, van Veldhuisen DJ. Cancer and heart disease: associations and relations. Eur J Heart Fail. 2019;21(12):1515–1525. doi: 10.1002/ejhf.1539. - DOI - PMC - PubMed
    1. Geisberg CA, Sawyer DB. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep. 2010;12(6):404–410. doi: 10.1007/s11906-010-0146-y. - DOI - PMC - PubMed
    1. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–1032. - PubMed
    1. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–361. - PubMed
    1. Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945–1960. doi: 10.1002/ejhf.1920. - DOI - PMC - PubMed

LinkOut - more resources